Cardiovascular Therapeutics / 2020 / Article / Tab 1

Review Article

Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials

Table 1

General characteristics of studies included in the network meta-analyses.

StudyGroup (treatment)No. of subjectsMean ageDisease statusCountryPopulationFollow-up durationOutcomes

Zhu et al. [36]ATO (20 mg)
86Ischemic strokeChinaChinese6 monthsLDL-C, TC, TG
Tunçez et al. [37]ATO (80 mg)
ROS (40 mg)
63 (ATO)
Acute myocardial infarctionTurkeyTurk4 weeksLDL-C, HDL-C, TC
Thondapu et al. [38]ATO (20 mg)
ROS (10 mg)
4354.2 (ATO)
57.5 (ROS)
De novo coronary artery diseaseUSA, Japan, and KoreaUNK1 yearLDL-C, HDL-C, TC, TG
Mostafa et al. [17]ATO (80 mg)
ROS (40 mg)
100 (ATO)
Acute coronary syndrome/dyslipidemiaArab Republic of EgyptEgyptians1 monthLDL-C, HDL-C, TC, TG
Zhao and Peng 2017 [24]ATO (10 mg)
ROS (5 mg, 10 mg)
414HypercholesterolemiaChinaChinese6 weeksLDL-C, HDL-C, TC, TG, ApoB
Canas et al. [39]PLA
38Type 1 diabetesUSAAmerican6 monthsLDL-C, HDL-C, TC, TG
Aydin et al. [40]ATO (80 mg)
ROS (20 mg)
120ST elevation myocardial infarctionTurkeyTurk40 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Moezzi et al. [18]PLA
SIM (40 mg)
7720-88DyslipidemiaIranIranian1 monthLDL-C, HDL-C, TC
Correa et al. [41]SIM (40 mg)
7918-70HypertensionBrazilBrazilian6 monthsLDL-C
Koh et al. [42]PLA
ROS (10 mg)
PRA (40 mg)
158UNKHypercholesterolemiaKoreaKorean2 monthsLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Nozue et al. [43]PIT (4 mg)
PRA (20 mg)
164Coronary artery diseaseJapanJapanese8 monthsLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Nohara et al. [44]ROS (5 mg)
PRA (10 mg)
298AdultCarotid intima-media thicknessJapanJapanese24 monthsLDL-C, HDL-C, TG
Lee et al. [45]ATO (20 mg)
ROS (10 mg)
271≧18 years oldMild coronary atherosclerotic plaquesKoreaKorean6 monthsLDL-C, HDL-C, TC, TG
Nicholls et al. [46]ATO (80 mg)
ROS (40 mg)
157818-75Coronary diseaseUSAAmericanUNK (endpoint time was during treatment)LDL-C, HDL-C, TC, ApoB, ApoA1
Saku et al. [47]ATO (10 mg)
ROS (2.5 mg)
PIT (2 mg)
22825-75HypercholesterolemiaJapanJapanese16 weeksLDL-C, HDL-C, TG
Hernández et al. [19]PLA
ATO (10/40 mg)
6245-75HypercholesterolemiaSpainSpanish3 monthsLDL-C, HDL-C, TC, TG
Tsutamoto et al. [48]ROS (2.5 mg)
ATO (5 mg)
Cardiac sympathetic nerve activity in nondiabetic patient with dilated cardiomyopathyJapanJapanese6 monthsLDL-C, HDL-C, TC, TG
Shimabukuro et al. [49]PIT (2 mg)
ATO (10 mg)
3130–79Type 2 diabetes mellitusJapanJapanese6 monthsLDL-C, HDL-C, TC, TG
Bulbulia et al. [50]PLA
SIM (40 mg)
2053640-80High risk of vascularBritainBritish3-5 yearsLDL-C, TC
Sansanayudh et al. [51]PIT (1 mg)
ATO (10 mg)
100≧18HypercholesterolemiaThailandThai8 weeksLDL-C, HDL-C, TC, TG
Bellia et al. [52]SIM (20 mg)
ROS (20 mg)
29Type 2 diabetesItalyItalian4 weeksLDL-C, HDL-C, TC, TG
Su et al. [53]SIM (40 mg)
ATO (10 mg)
15151–72Type 2 diabetes mellitusChinaChinese12weeksLDL-C, HDL-C, TC, TG
Ose et al. [25]PIT (2 mg, 4 mg)
SIM (20 mg, 40 mg)
85718–75Hypercholesterolemia or dyslipidemiaRussia, Norway, UK, Finland, ItalyMultiple groups12 monthsLDL-C
Kurabayashi et al. [54]ATO (10 mg)
ROS (5 mg)
405≧20HypercholesterolemiaJapanJapanese8 weeksLDL-C, HDL-C, TC, TG
Young et al. [55]ATO (40 mg)
ROS (20 mg)
Coronary stenosisKoreaKorean1 yearLDL-C, HDL-C, TC, TG
Kyeong et al. [56]ATO (20 mg)
ROS (10 mg)
Acute coronary syndromeKoreaKorean40 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Kom et al. [57]PLA
ATO (40 mg)
2435-60HypercholesterolemiaGermanyGerman6 weeksLDL-C, HDL-C, TC
Marketou et al. [58]SIM (40 mg)
ATO (40 mg)
8835-70HyperlipidemiaGreeceGreek3 weeksLDL-C, HDL-C, TG
Pedersen et al. [59]SIM (20 mg)
ATO (80 mg)
8888≦80Myocardial infarctionEuropeEuropean5 yearsLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Sirtori et al. [60]ATO (10 mg)
PRA (20 mg)
86UNKHyperlipidemiaItalyItalian12 weeksLDL-C
Nissen et al. [61]PRA (40 mg)
ATO (80 mg)
65430-75Coronary atherosclerosisUSAAmerican18 monthsLDL-C, HDL-C, TC, TG
Durazzo et al. [20]PLA
ATO (20 mg)
100UNKAfter vascular surgeryBrazilBrazilian45 daysLDL-C, HDL-C, TC, TG
Bevilacqua et al. [62]FLU (80 mg)
ATO (20 mg)
10045 to 71Type 2 diabetes mellitusItalyItalian3 monthsLDL-C, HDL-C, TG, ApoB, ApoA1
Schwartz et al. [26]ROS (5 mg, 10 mg)
ATO (10 mg)
382≧18Hypercholesterolemia coronary heart diseaseUS
12 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Colhoun et al. [63]PLA
ATO (10 mg)
281940–75Type 2 diabetes mellitusUK
4 yearsLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Wissen et al. [64]SIM (40 mg)
ATO (80 mg)
325UNKHeterozygous familial hypercholesterolemiaNetherlandDutch2 yearsLDL-C, HDL-C, TC, TG
Isaacsohn et al. [27]PLA
SIM (20 mg/40 mg/80 mg)
19518-70HypertriglyceridemiaUSAAmerican6 weeksLDL-C, HDL-C, TC
McCrindle et al. [65]ATO (10 mg-20 mg)
South Africa
26 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Kadikoylu et al. [66]ATO (10-20 mg)
SIM (10-20 mg)
6139–74Primary hypercholesterolemiaUSA
24 weeksLDL-C, HDL-C, TC, TG
Manuel-Y-Keenoy et al. [67]ATO (40 mg)
24UNKType 1 diabetesBelgiumEuropean12 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Sever et al. [68]PLA
ATO (10 mg)
1030640–79HypertensionLondonBritish5 yearsLDL-C, HDL-C, TC, TG
Winkler et al. [69]PLA
FLU (80 mg)
8939–86Type 2 diabetes mellitusGermanyGerman8 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Tan et al. [21]PLA
ATO (10 mg-20 mg)
80UNKType 2 diabetes mellitusHong KongChinese6 monthsLDL-C, HDL-C, TC
Wang and Ting [70]ATO (10 mg)
5460Elevated LDL cholesterolTaiwanChinese8 weeksLDL-C, HDL-C, TC, TG
Schrott et al. [71]PLA
2247-72Modestly overweight (potential tendency of dyslipidemia)USAAmerican14 daysLDL-C, HDL-C, TC, TG
Serruys et al. [72]PLA
FLU [80 mg (40 mg bid)]
After successful coronary balloon angioplastyNetherlandsDutch26 weeksLDL-C
Mitropoulos et al. [28]PLA
SIM (20 mg, 40 mg)
16240-75Coronary heart diseaseLondonBritish2 yearsLDL-C, HDL-C, TC, TG
Lam et al. [73]PLA
LOV (20 mg~60 mg)
34UNKHypercholesterolemiaChinaChinese1 yearLDL-C, HDL-C, TC, TG, ApoB, ApoA1
Contermans et al. [74]SIM
24HypercholesterolemiaHollandDutch18 weeksLDL-C, HDL-C, TC, TG
Mcdowell et al. [75]PLA
SIM (10 mg-40 mg)
27UNKPrimary hypercholesterolemiaIrelandIrish12 weeksLDL-C, HDL-C, TC, TG, ApoB, ApoA1

PLA: placebo; SIM: simvastatin; FLU: fluvastatin; ATO: atorvastatin; ROS: rosuvastatin; LOV: lovastatin; PRA: pravastatin; PIT: pitavastatin; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride; ApoA1: Human Apolipoprotein A-1; ApoB: Human Apolipoprotein B; UNK: unknown.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.